PharmaDiagnostics, a developer of label-free screening technology that does not require specialised instrumentation, has appointed Dr Sylviane Boucharens as director of assay development. She joins from Merck’s MSD site in Newhouse, Scotland, where she was head of global compound repository and in vitro screening.
Boucharens will play a central role in driving the growth of PharmaDiagnostics’ assay product range, and in developing business globally. She worked at Merck from 2000 to 2011. She started her career in the pharmaceutical industry in 1995 when she joined the Immunology Department in the Laboratoires Fournier (Dijon, France).
PharmaDiagnostics appoints director of assay development
Former pharma department head joins Belgian firm
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Accelerating the development of bispecific antibodies
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Manufacturing
Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform
The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering
Manufacturing
Symbiosis completes full ICH climatic zone coverage with new stability chamber addition
Sterile injectable CDMO Symbiosis Pharmaceutical Services has installed a 30°C stability chamber at its Stirling facility, completing its coverage of all four ICH-defined climatic zones and strengthening its commercial drug product supply capabilities for global markets